Figure 2. Primary outcome (A), the bilateral endoscopic nasal
polyp score at 20 weeks treatment is significantly lower compared to
baseline in benralizumab group (P=0.004) but not placebo (P=0.166). (B)
Similarly, CT polyp score is lower in the benralizumab group (P=0.012)
but not placebo (P=0.233).
The reduction in polyp size and CT score were not uniform among all
subjects treated with benralizumab. The benralizumab treated group
ranged from no improvement to a three-point reduction in total bilateral
endoscopic polyp score. CT score reduction was likewise variable among
the benralizumab treated group. Figure 3, shows the endoscopic image and
sinus CT scan of two representative patients that improved with
benralizumab treatment.